Carlo Acutis, the first Roman Catholic saint of the millennial generation, was in the right place at the wrong time. Carlo Acutis When he developed the rare, aggressive blood cancer called acute ...
Combining all-trans retinoic acid (ATRA) with arsenic trioxide (ATO) and idarubicin significantly improved event-free survival (EFS) compared with the standard treatment of ATRA and ...
Acute promyelocytic leukaemia (APL) represents a unique and once highly fatal subtype of acute myeloid leukaemia that is now considered among the most curable forms of haematological malignancies.
Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...
In a phase 3 trial of 133 patients with high-risk acute promyelocytic leukemia (APL), all-trans retinoic acid and arsenic trioxide (ATRA-ATO) therapy demonstrated superior 2-year event-free survival ...
Researchers at Zhejiang University School of Medicine have identified a single point mutation in the normal PML gene that can block the effect of arsenic trioxide, a frontline drug for acute ...
Anti-tumor activity of CoREST inhibitor, JBI-802 (dual epigenetic modifier of LSD1/HDAC6): An opportunity to treat essential thrombocythemia and MPN/MDS patients with thrombocytosis in ongoing phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results